Identification of CD318 (CDCP1) as novel prognostic marker in AML
Jonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, Malte Roerden, Gundram Jung, Helmut R Salih, Melanie Märklin, Joseph Kauer, Jonas S Heitmann, Ilona Hagelstein, Clemens Hinterleitner, Malte Roerden, Gundram Jung, Helmut R Salih, Melanie Märklin, Joseph Kauer
Abstract
Genetic and morphological markers are well-established prognostic factors in acute myeloid leukemia (AML). However, further reliable markers are urgently needed to improve risk stratification in AML. CD318 (CDCP1) is a transmembrane protein which in solid tumors promotes formation of metastasis and correlates with poor survival. Despite its broad expression on hematological precursor cells, its prognostic significance in hematological malignancies so far remains unclear. Here, we evaluated the role of CD318 as novel prognostic marker in AML by immunophenotyping of leukemic blasts. Flow cytometric evaluation of CD318 on leukemic cells in 70 AML patients revealed a substantial expression in 40/70 (57%) of all cases. CD318 surface levels were significantly correlated with overall survival in patients receiving anthracycline-based induction therapy or best available alternative therapy. Using receiver-operating characteristics, we established a cut-off value to define CD318lo and CD318hi expression in both cohorts. Notably, high CD318 expression correlated inversely as prognostic marker in both treatment cohorts: as poor prognostic marker in patients receiving intense therapy, whereas upon palliative care it correlated with better outcome. In conclusion, FACS-based determination of CD318 expression may serve as novel prognostic factor depending on implemented therapy in AML patients.
Keywords: AML; CD318; CDCP1; Prognosis; Risk stratification.
Conflict of interest statement
The authors declare that they have no conflict of interests.
Figures
References
An official website of the United States government
Here's how you know The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Sorry, the server encountered an internal error or misconfiguration and was unable to complete your request.
Try one of these options instead:
- NCBI Home
- Contact Help Desk
- Search
National Library of Medicine
Source: PubMed